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Rheumatoid arthritis affects about 24.5 million people worldwide as of 2015. Modern medicine still eludes satisfactory 
cure for this problem. Therefore, world is looking forward for some traditional medicines in this direction. In the present 
work, therapeutic efficacy of a Unani compound drug Habb-e-Asgand has been evaluated at Regional Research Institute of 
Unani Medicine (RRIUM), Aligarh, during 2016-2018. A total of 68 patients were selected from the lot of patients attending 
outpatient department (OPD). The drug Habb-e-Asgand was given 2 Tablets for 84 days and results evaluated statistically 
by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The results of the present study were evaluated on 
clinical, biochemical, and haematological parameters have amply demonstrated that the drug Habb-e-Asgand is 
therapeutically effective in the treatment of Waja ‘al-mafasil (rheumatoid arthritis). The study has also shown the drug non-
toxic and safe. Further studies are suggested in large population. 
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Wajaul Mafasil also known as 'Gatthia' is a chronic 
inflammatory disease in which joints become painful 
and bulging with decreased normal activity. Soo-e-
Miza (Derangement of temperament) is the main 
etiological factor of Waja-al Mafasil according to 
Tib-e-Unani. Depending upon the madda affecting the 
joints, four types of diseases are commonly produced; 
Damawi (Sanguine), Safrawi (Bilious), Saudawi 
(Melancholic) and Balghami (Phleghmatic). Mostly 
two or more Akhlat (Humours) constitute the 
‘Madda’, with changes in preponderance of a Khilt 
(Humour) in various phases of the disease
1
.  
Rheumatoid arthritis affected about 24.5 million 
people as of 2015
2
. This is between 0.5 and 1% of 
adults in the developed world with 5 and 50 per 
100,000 people newly developing the condition each 
year
3
. Rheumatoid arthritis strikes during the most 
productive years of adulthood between the 20-40 
years of age
4
. The prevalence of Rheumatoid arthritis 
varies between 0.3% and 1% around the globe and 
0.28-0.7% in India
5




In the year 2016, the global burden of disease 
(GBD) proves that the musculoskeletal diseases 
accounted for the second highest contribution for the 
disability around the world. There are around  
20-30% of people around the globe with a painful 
musculoskeletal condition
7
. It is a state of chronic 
inflammation as a result of damage of joints, disability 
with morning stiffness in the joints of hand, feet, knee 
and ankle joints. According to Unani claimed text, 
accumulation of ‘madda’ (substance) in joints, which is 
neither absorbed nor expelled is due to absence of 
Quawwat-e-Jazibah (power of absorption) and 
Quawwat-e-dafia (power of expulsion)
8
.  
Several important modern drugs are being used for 
rheumatoid arthritis treatment like glucocorticoids, 
DMARDS, NSAIDS, like cyclophosphamide, 
intramuscular gold, sulfasalazine and methotrexate but 
had side effects of stomach ulcers, GIT bleeding, 




Now attention is diverted to herbal and Unani 
drugs due to their versatile role in the management of 
rheumatoid arthritis with no or negligible side effects 
besides being cost effective
10
. Keeping in view the 
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above facts, the therapeutic efficacy and safety of a 
Unani compounds drugs–Habb-e-Asgand was evaluated 
on scientific lines in the present study Table 1.  
 
Materials and Methods 
This study was conducted during 2016-2018 at 
RRIUM, Aligarh. Unani compound drug- Habb-e-
Asgand was procured from CCRUM, New Delhi. 
Sixty eight patients of 18-65 years of either sex were 
selected from the lot of patients attending the Out 
Patient Department (OPD) with signs and symptoms 
related to Waja-al Mafasil. The follow-ups for clinical 









 -day. In total 204 
cases were screened, out of these 141 were registered 
on the basis of inclusion and exclusion criteria. 68 cases 
finally completed the study. The efficacy and safety of 
Unani compound drug-Habb-e-Asgand was evaluated 
on the demographical, biochemical and haematological 
parameters to combat Waja ‘al-Mafasil.  
 
Selection criteria  
Patients were enrolled on the basis of following 
inclusion and exclusion criteria:  
 
Inclusion Criteria 
• Patients of either sex in the age group 18-65 years. 
• Patients having Waja‘al-Mafāsil (rheumatoid 
arthritis) as defined by the following ACR-Eular 
criteria 
• Definite clinical synovitis (pain, swelling, 
tenderness) in at least 1 joint. 
• Absence of an alternative diagnosis for the 
observed synovitis (arthritis). 
• A total score of at least 6 from the individual scores 
in 2 domains: 
• Number and site of involved joints (range 0-5) 
• Duration of symptoms (range 0-1) 
 
Exclusion Criteria 
• Rheumatoid arthritis with extra-articular 
manifestations, joint deformities, and advanced 
radiological lesions (e.g., joint subluxation and 
collapse). 
• Obese subjects (BMI ≥30) 
• History or clinical evidence of any systemic 
inflammatory condition other than RA that may 
interfere with evaluation. 
• History or clinical evidence of any serious systemic 
illness, DM, TB, disseminated/ complicated  
Herpes zoster (e.g., multi-dermatomal involvement, 
ophthalmic zoster, CNS involvement, post- 
Herpetic neuralgia) or HIV infection that could 
interfere with the interpretation of data. 
• Are currently receiving or have received intra-
articular treatment (e.g., corticosteroids or hyaluronic 
acid), oral or parenteral corticosteroids, or NSAIDs 
within 2 weeks, DMARDs or anticipated IFN 
therapy within 4 weeks prior to study entry.  
• Screening laboratory test values, including 
creatinine, blood urea nitrogen (BUN), bilirubin 
outside the reference range and SGOT, SGPT 
raised >2 times the ULN that in the opinion of the 
investigator, could pose an unacceptable risk to the 
participant. 
• History of hypersensitivity to study drug or any of 
its ingredients. 
• Pregnant and lactating women 
• History of addiction (alcohol, drugs). 
 
Ethical consideration 
Written informed consent of all patients included  
in the study was obtained. This project was registered 
in Clinical Trials Registry-India (CTRI) (Ref: 
2016/07/011657 (H).  
 
Drug, dose and mode of administration 
Two tablets each of (650 mg) of Habb-e-Asgand 
were given to patients twice a day after meals for a 
period of 84 days. The biochemical and hematological 
investigation were conducted on day one and at the 
end of the study i.e., after 84-days.  
 
Assessment of Mizaj (Temperament) 
Assessment of Mizāj (temperament) was done at 
baseline and at the end of treatment (Tabe 5). 
 
Follow-up evaluation  
The patients were measured clinically at every 2 
weeks, i.e., at 14, 28, 42, 56, 70 and 84 days.  
The subjective and objective clinical observations will 
be recorded in the follow-up sheet. 






Ajwayin Desi  Trachyspermum ammi  20 g 
Asgand  Withania somnifera  40 g 
Bidhara  Argyreia speciosa  40 g 
Peepla Mool  Piper longum  20 g 
Pipal Kalan  Ficus religiosa 20 g 
Zanjabeel Zingiber officianale 40 g 
Satawar Asparagus racemosus 40 g 
Musli Siyah  Curculigo orchioides 20 g 
Gur  Jaggery 50 g 
 




Criteria for assessment of efficacy 
To assess the response of treatment in patients of 







Visual analogue scale (VAS) 
In this clinical study, the VAS (0-100 mm) for joint 
pain and the DAS28 (0-10) for clinical disease 
activity was used as a measure of improvement in 
rheumatoid arthritis to evaluate the efficacy of studied 
drug. 
Joint pain was measured on a 0-100 mm visual 
analogue scale (VAS), for which horizontal VAS was 
used. 
Visual Analogue Scale (VAS) 
0 10 20 30 40 50 60 70 80 90 100 mm 
 
No  Mild  Moderate  Severe  Very severe
  Worst possible 
Pain Pain  Pain  Pain  Pain  Pain 
 
• Joint tenderness: Nil/ Mild/Moderate/Severe 
 0 1 2 3 
• Joint swelling: Nil/ Mild/Moderate/Severe 
 0 1 2 3 
• Early morning stiffness (EMS): Nil / Mild / 
Moderate / Severe 
0 1 2 3 
0= Nil 
1=Morning stiffness of 15-30 min duration. 
2= Morning stiffness of >30 min and <60 min 
duration. 
3= Morning stiffness of >60 min duration 
 
• Restriction of joint movement 
0= Nil 
1= Mild >25% restriction of movement. 
2= Moderate 25 to 50% restriction of movement. 
3= Severe >50% restriction of movement. 
 
Patient’s global assessment of disease activity (on a VAS of 0-
100 mm) 
Visual analogue scale (VAS) 
0 10 20 30 40 50 60 70 80 90 100 mm 
Not Active  Mildly  Moderately  Severely
  Very severely  Extremely 
At all  active  active active   active  active 
 
Disease activity score in 28 joints (DAS28)11  
An assessment of DAS involves the physician 
looking at the number of tender and swollen joints 
(out of the 28) the patient’s global assessment (PGA) 
of disease activity on VAS (indicated by marking a  
0-100 mm horizontal line between not active and 
extremely active). The DAS28 provides with a 
number between 0 and 10.  
 
Assessment of safety 
 
Biochemical analysis  
Serum glutamate pyruvate transaminase (SGPT, 
E.C. 2.6.1.2) and serum glutamate oxaloacetate 
transaminase (SGOT, E.C. 2.6.1.1.)
12
, serum alkaline 






















Haematological parameters were done
20
. It included 
haemoglobin (Hb), erythrocyte sedimentation rate 
(ESR), total leucocytes counts (TLC), red blood 
corpuscles (RBC) and differential leucocytes counts 
(DLC): polymorphs, lymphocyte and eosinophil 
counts.  
 
Collection of blood serum 
Blood samples were collected by puncturing the 
vein at each investigation. 1.0 mL of blood with 
ethylene diamine tetra acetic acid (EDTA) was used 
for various haematological parameters and another 
2.0-2.5 mL of blood sample was allowed to clot and 
serum was separated by centrifugation, which was 
used for various biochemical parameters. Biochemical 
and haematological investigations were carried out. 
 
Statistical analysis 
Data were analyzed statistically by one-way 
analysis of variance (ANOVA) followed by Dennett’s’ 
test. The values were considered significant when the p-
value was found less than 0.05. 
 
Results and Discussion 
 
Demographic study 
Out of 68 patients of Waja‘al-Mafasil (rheumatoid 
arthritis), 11(16.18%) were male and 57 (83.82%) 
female, which shows that female have higher 
incidence as compared to male. Hormones in both 
genders may play a role in either preventing or 
triggering the disease
21
. The patients of 46-55 years 
(mean age 40.82 years) of male and 36-45 years 
(mean age 39.86 years) age group of female are more 
susceptible to rheumatoid arthritis (Table 2). Non-
Vegetarians had more incidences 49 (72.06%) than 
Vegetarians 19 (27.94%) (Table 3). Middle income 
group had more incidences 47 (69.12%) than lower 




income group 19 (27.94%) followed by high income 
group (Table 4). The incidence was found more in 
Balghami (Phlegmatic) patients 58 (85.29%) as 
compared to Safrawi (Bilious) 07 (10.3%) followed 
by Damwi (Sanguine) 03 (4.41%) (Table 5). Similar 






Joint pain score 
When Unani compound drug- Habb-e-Asgand was 
given to the patients orally 2-Tablet (650 mg each) 
twice a day after meal for 84-days, a significant 
reduction in joint pain score 10.17 % (p<0.05)  
on 42
th





-day and 58.04% (p<0.0001) 84
th
-day 
had been observed and these were compared with  
the values of baseline and different follow-up of 
treatment (84
th
-days) (Table 6). Similar observation 





A significant reduction in joint tenderness 6.41% % 
(p<0.05) on 42
th





-day and 49.36% (p<0.0001) 
84
th
 day had been observed, while slight reduction in 
joint tenderness 1.92%, 3.21%, on 14
th
 day and 28
th
 
day, respectively but no significant changes had been 
observed and these were compared with the values  
of baseline and different follow-up of treatment 




Table 5 — Data showing arrangement of patients according to 
temperament in Waja-al Mafasil (rheumatoid arthritis) patients. 
Type of Temperament  Number of cases & % 
Damvi (Sanguine) 03 (4.41%) 
Balghami (Phlegmatic)  58 (85.29%) 
Safrawi (Bilious) 07 (10.3%) 
Saudawi (Melancholic) Nil 
 
Joint swelling 
A significant reduction in joint swelling 37.95% 
(p<0.01) on 56
th





-day had been observed, 
while slight reduction in joint swelling 20.48%, 







respectively but no significant changes had been 
observed in the earlier days of treatment; and these 
were compared with the values of baseline  
and different follow-up of treatment (Table 6). 





Early morning stiffness (EMS) 
A significant reduction in early morning stiffness 
14.55% (p<0.05) on 42
th
-day, 35.15% (p<0.0001) 
56
th





-day had been observed, while 





-day respectively but no significant changes 
had been observed and these were compared with  
the values of baseline and different follow-up  
of treatment (Table 6). Similar findings had been 




Joint s core visual analogue score (VAS) 
A significant reduction in joint score VAS 23.14% 
(p<0.0001) on 56
th
-day, 35.64% (p<0.0001) 70
th
-day 
and 56.1% (p<0.0001) 84
th
-day had been observed, 
while slight reduction in joint score VAS 9.91% on 
42
th
-day but no significant changes had been 
observed and these were compared with the values 
of baseline and different follow-up of treatment 




Table 2 — Demographic data showing arrangement of Waja‘al-Mafasil (rheumatoid arthritis) patients according to age and sex. 
Age group (In years) Number of females & % Number of males & % Total number & % 
15-25 05 (8.77%) 01 (9.1%) 06 (8.82%) 
26-35 12 (21.05%) 03 (27.27%) 15 (22.06%) 
36-45 27 (47.37%) 03 (27.27%) 30 (44.12%) 
46-55 11 (19.30%) 02 (18.18%) 13 (19.13%) 
56-65 02 (3.51%) 02 (18.18%) 04 (5.88%) 
Total, % & Mean ± SD 57 (83.82 %), 39.86 ±9.19 11 (16.18%), 40.82±13.7 68 (100.00%), 40.34 ±0.68 
 
Table 3 — Demographic data showing arrangement of Waja‘al-
Mafasil (rheumatoid arthritis) patients according to dietary habits. 
Dietary habits  Number of cases & % 
Vegetarian 19, (27.94%) 
Non-Vegetarian  49 (72.06%) 
 
Table 4 — Demographic data showing arrangement of Waja-al 
Mafasil (rheumatoid arthritis) patients according to social status. 
Social status  Number of cases & % 
High income group  02 (2.94%) 
Middle income group  47 (69.12%) 
Lower income group 19 (27.94%) 
 





A significant reduction in total score 36.98% 
(p<0.0001) on 70
th
-day and 56.84% (p<0.0001) 84
th
-
day had been observed, while slight reduction in total 
score 2.22%, on 28
th
-day but no significant changes 
had been observed and these were compared with  
the values of baseline and different follow-up of 





28-joint count activity score 
A significant reduction in 28-joint count activity 
score 37.13% (p<0.0001) had been observed as 
compared with the values of baseline and 84
th
-day 
treatment (Table 7). Similar observation had been 






Liver function tests and kidney function tests 
When Unani compound drug- Habb-e-Asgand was 
given to the patients orally 2 Tablets (650 mg each) 
twice a day after meal for 84
th
-days, no significant 
alterations in liver function tests as well as kidney 
function tests had been observed. Therefore, it can be 
inferred that it did not induce any negative or 
unfavorable response. The safety of the drug is 
therefore conformed (Table 8).  
 
Serum uric acid, rheumatoid factor and C-reactive protein 
No significant change but slight reduction in the 
level of uric acid 2.55% and rheumatoid factor (R-
factor) 22.74% had been observed, while a significant 
decrease in the level C-reactive protein 17.24% 
(p<0.05), had been observed (Table 9). Similar report 





When Unani compound drug-Habb-e-Asgand was 
given to the patients orally 2 Tablets (650 mg each) 
twice a day after meal for 84
th
-days, no significant 
changes in the level of (Hb), (RBC), (TLC), (ESR) 
and (DLC) had been observed. These were compared 
with the values of baseline and different follow-up of 
treatment (Table 10). 
Table 6 — Effect of Habb-e-Asgand on symptoms in Waja-al Mafasil (rheumatoid arthritis) patients. [*p<0.05& **p<0.01 are 

















Joint pain  
score 
44.85±13.44 45.15±13.87▪ 44.56±14.19▪ 40.29±13.38* 34.85±12.28*** 27.94±11.27*** 18.82±10.58*** 
Joint  
tenderness 
1.56±0.58 1.53±0.56▪ 1.51±0.56▪ 1.46±0.56* 1.12±0.53*** 0.85±0.50*** 0.79±0.59*** 
Joint 
 swelling 
1.66±1.83 1.32±0.63▪ 1.35±0.62▪ 1.26±0.59▪ 1.03±0.49** 0.75±0.53*** 0.34±0.51*** 
Early morning  
stiffness 
1.65±0.71 1.62±0.65▪ 1.63±0.62▪ 1.41±0.67* 1.07±0.55*** 0.81±0.50*** 0.54±0.58*** 
Joint score  
(VAS) 
43.09±17.3 43.24±17.23▪ 42.94±17.37▪ 38.82±16.71▪ 32.79±15.63*** 27.35±13.34*** 18.97±10.97*** 
Total  
score 
48.57±16.24 48.03±17.07▪ 47.49±17.08▪ 43.24±16.79* 43.90±16.8▪ 30.22±13.43*** 21.00±11.04*** 
 
 
Table 8 — Effect of Unani compound drug Habb-e-Asgand in the levels of SGPT, SGOT and serum alkaline phosphatase, blood urea 









Blood Urea Nitrogen 





(Baseline) (1st-Day) 29.33±11.01 27.73± 13.86 81.38±32.95 12.1±6.40 0.91±0.17 0.69±0.21 
Post-treatment (84-Days) 28.28±13.9▪ 32.23±15.27▪ 79.48±27.22▪ 10.01±3.55▪ 0.95±0.21▪ 0.70±0.20▪ 
 
Table 9 — Effect of Unani compound drug Habb-e-Asgand in the levels of uric acid, R- factor and C- reactive protein in Waja’al Mafasil 
(rheumatoid arthritis) patients. [*p<0.05 is significant and ▪P is not significant] 
ParameterGroup Uric Acid(mg %) RF-Factor (IU/mL) C-Reactive Protein(mg /dL) 
(Baseline) (1st-Day) 4.31±1.39 13.81±16.69 18.56±10.51 
Post- treatment (84-Days)  4.2±1.26▪ 10.67±11.67▪ 15.36±8.84* 
Table 7 — Effect of Habb-e-Asgand in 28-joint activity score in 
Waja-al Mafasil (rheumatoid arthritis) patients.  
[***p<0.001 is highly significant]. 
28-joint count activity score Variable, (Mean ± SD) 
Baseline (1st - Day) 5.01±1.32 
Post-treatment (84th –days) 3.15±0.89*** 
 
 





The presently available synthetic drugs reduce 
inflammation in rheumatoid arthritis but produce 
adverse side effects. These drugs have a tendency to 
develop tolerance slowly and therefore the dose is 
increased to marked levels. Thus, there is an urgent 
need to identify and validate herbal drugs and their 
active constituents, to be used as potential therapeutic 
agents for treatment of rheumatoid arthritis. 
On the basis of this study, it may be concluded that 
Unani compound drug-Habb-e-Asgand possesses anti-
inflammatory, analgesic and anti-rheumatic activity, 
for which significant improvement in sign, symptoms 
and C-reactive protein was observed. It can also be 
inferred that the drug is safe as it did not induce any 
toxic effect, particularly on liver and kidney functions. 
Further studies are warranted in large group. 
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